Navigation Links
Dr Stephan Rietiker Joins BioCeramic Therapeutics
Date:1/9/2009

LONDON, January 9 /PRNewswire/ -- UK medical technology company BioCeramic Therapeutics Ltd is delighted to announce that Dr Stephan Rietiker has joined the company's Board of Directors. Dr Rietiker is widely recognized as a leading authority in BioCeramic Therapeutics' targeted sectors, particularly as former President and CEO of Centerpulse (formerly Sulzer Medical). His appointment follows the recent appointment of another renowned figure, Sir Richard Sykes, as Chairman of its Board of Directors and strengthens the company's management as it embarks on a new fundraising round to take its products through clinical trials.

"Given my professional background as a healthcare executive and in particular at Centerpulse, my primary focus is on getting involved in companies with leading edge technologies. As R&D activities in the biomaterials' arena are visibly gaining momentum, I'm delighted to be part of this fascinating venture. I fully believe in the technology and its future potential. Hence, I look forward to supporting the management team in efficiently reaching its strategic milestones and in creating significant value, both for patients and shareholders."

BCT is a pioneer in the exciting new field of regenerative medicine, bringing together some of the world's best materials scientists doctors, biologists and chemists in both private and public sectors. BCT is developing two families of implants designed to promote tissue regeneration. Initial applications are in orthopaedics and oral care, with plans to extend this to a wide range of other tissues important in human diseases.

Daniel Green, BCT's CEO, said: "I am delighted to welcome Stephan to the team. His input will be invaluable as we look to move our first BCT pipeline products through to clinic. Currently we are both exploring several licencing opportunities and embarking on a new fundraising round."

    Corporate 
'/>"/>
SOURCE BioCeramic Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dr. John Stephen Osika, HIV/AIDS and Infectious Disease Expert, Joins Abt Associates
2. GEN Joins Charles Darwin 2009 Celebration
3. BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative
4. Maureen Mo Zilly Joins the Varian Medical Systems Government Affairs Team as Director, Federal Affairs
5. Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons
6. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
7. Pharos Innovations Joins Partnership to Fight Chronic Disease
8. Recognized Dermatology Expert Dr. Zoe Draelos Joins Histogen Scientific Advisory Board
9. Ethan Weiss, M.D., Joins Bionovos Scientific Advisory Board
10. Benjamin Custodio Joins Millennium Biotechnologies to Expand International Sales
11. Jerome Wilson Joins PRA Internationals Late Phase Service Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Lexington,Kentucky and Queens, New York (PRWEB) October 02, ... is pleased to announce funding received to ... pathway in Alzheimer’s disease. A grant award from ... Institute on Aging (NIA), National Institutes of Health ... as Novel AD Therapeutics." The company also received ...
(Date:10/2/2014)... (PRWEB) October 02, 2014 Permian Plastics, ... in the St. Louis, Missouri, area on October 24th, ... become a leading plastic injection molder in the Midwest. ... and is a supplier to many Fortune 500 clients. ... support every step of the way, from concept to ...
(Date:10/2/2014)... 2014 At a time when many are ... has introduced a new kind of squeeze aimed at containing ... Scienceware® Squeeze Rite™ Wash Bottle , catalog no. F11717-0030. ... the bottle reduces the waste of reagents, solutions and other ... , “Easier to squeeze when compared to standard 500ml bottles, ...
(Date:10/2/2014)... 2014  NKT Therapeutics today announced that the ... Track designation to NKTT120, the company,s lead therapeutic ... disease.  NKTT120 is a humanized monoclonal antibody that ... that has been demonstrated to be a key ... sickle cell disease.  Fast Track designation is intended ...
Breaking Biology Technology:Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 3Permian Plastics LLC Celebrates 20 Years As Leading Manufacturer of Plastic Molds 2New Wash Bottle Reduces Waste of Reagents, Solutions, and Other Liquids 2FDA Grants Fast Track Designation to NKT Therapeutics' NKTT120 for the Treatment of Sickle Cell Disease 2
... PARK, N.Y., Feb. 6 MINRAD International,Inc. (Amex: ... Company received a notice from,NYSE Alternext US LLC (the ... stock of the Company from the Exchange by filing ... to Section,1009(d) of the NYSE Alternext US Company Guide. ...
... Sky One Medical,Inc. ("China Sky One Medical" or ... leading,fully integrated pharmaceutical company producing over-the-counter drugs in,the ... the Company,s,Chief Financial Officer, Mr. Yu-bo (Stanley) Hao, ... Roth 21st Annual OC Growth Stock,Conference in Dana ...
... BIRMINGHAM, Ala., Feb. 6 BioCryst Pharmaceuticals, Inc. (Nasdaq: ... the fourth quarter and year ended December 31, 2008. ... months ended December 31, 2008, the Company reported collaborative ... compared to $28.2 million for the three months ended ...
Cached Biology Technology:MINRAD Receives Notice That NYSE Alternext Intends to File Delisting Application With Securities and Exchange Commission 2MINRAD Receives Notice That NYSE Alternext Intends to File Delisting Application With Securities and Exchange Commission 3China Sky One Medical, Inc. CFO to Present at Roth Conference 2China Sky One Medical, Inc. CFO to Present at Roth Conference 3BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 2BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 3BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 4BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 5BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 6BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 7BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 8BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 9
(Date:9/30/2014)... to using marijuana, new research, involving mice and published ... Journal of Leukocyte Biology , suggests that just ... should. That,s because a team of Italian scientists have ... long-term damage to the immune system. This damage may ... as multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra Automation, ... for the biotech and power generation industries, ... RECONN Bioprocess Manager, an easy-to-use and cost-effective ... towards bioprocess development laboratories. ... bioreactor and analyzer systems. Accessing and consolidating ...
(Date:9/29/2014)... study confirms that the exposure to tar tended to ... regular cigarettes. Similarly, exposure to nicotine tended to ... type of cigarette in several countries around the world. ... toxic chemicals in the smoke of these cigarettes are ... levels of chemicals in the smoke are not necessarily ...
Breaking Biology News(10 mins):Adolescent exposure to thc may cause immune systems to go up in smoke 2Spectra Automation Introduces RECONN Bioprocess Manager 2Slim cigarette smokers not exposed to more harmful chemicals 2
... a group of human subjects to operate a robot-controlled joystick, ... "learns" to control certain muscle movements, the more likely it ... results, the investigators say, could alter rehabilitation approaches for people ... , In a report on the work in the ...
... and exercise performance measures of trained cyclists at high ... a lot -- up to 45% -- while others ... level. , Ten cyclists who took sildenafil at altitude ... kilometers by 15% compared to placebo trials at altitude. ...
... for breast cancer do not increase their life expectancy ... analysis by researchers from UC Davis, UCSF, the University ... addition, the researchers showed that tamoxifen is an extraordinarily ... per year of life saved. The study will be ...
Cached Biology News:New approach to vaccine development provides potent, long-lasting immunity 2New approach to vaccine development provides potent, long-lasting immunity 3Viagra improves high altitude exercise performance up to 45% for some 2Viagra improves high altitude exercise performance up to 45% for some 3Viagra improves high altitude exercise performance up to 45% for some 4Tamoxifen for breast cancer prevention does not benefit most women 2Tamoxifen for breast cancer prevention does not benefit most women 3
... series of refrigerated cold traps offers a ... low volatility/aqueous solvents or high volatility solvents. ... vacuum concentrators/centrifugal evaporators. Also used for maintaining ... as used in electron microscopes. Can be ...
... Refrigerated Vapor Trap is specifically designed ... solvents such as DMSO and DMF ... constant temperature refrigeration system set at ... conditions for DMSO, while completely eliminating ...
96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
Thermo Forma provides an array of accessory Racks for the Cryo/CryoPlus 16" Diameter storage system. To maximise inventory capacity a Jumbo Arrowhead configuration is recommended. You may choose betw...
Biology Products: